|
Trade Name | nAbCyte Anti-AAVRh74var HB-FE Assay |
Classification Name | assays to detect pre-existing antibodies to adeno-associated virus (aav) viral vectors |
Generic Name | assays to detect pre-existing antibodies to adeno-associated virus (aav) viral vectors |
Applicant |
LabCorp Drug Development |
100 perimeter park drive, ste c |
morrisville, NC 27560 |
|
HDE Number | H230005 |
Date Received | 07/26/2023 |
Decision Date | 04/25/2024 |
Product Code | |
Advisory Committee |
Hematology |
Clinical Trials |
NCT03861273
|
Supplement Type | hde original |
Expedited Review Granted? | No |
Combination Product | No |
Approval Order Statement Approval for nabcyte anti-aavrh74var hb-fe assay: the nabcyte anti-aavrh74var hb-fe assay for beqvez™ (fidanacogene elaparvovec) eligibility in moderate to severe hemophilia b, or nabcyte anti-aavrh74var hb-fe assay, is a cell-based qualitative in vitro companion diagnostic device intended for the detection of neutralizing antibodies to the aavrh74var capsid in serum specimens from adult patients previously diagnosed with moderate to severe hemophilia b to determine eligibility for treatment with the hemophilia b gene therapy, beqvez (fidanacogene elaparvovec). Patients who test positive for neutralizing antibodies to the aavrh74var capsid are not eligible for treatment with beqvez (fidanacogene elaparvovec). Patients who test negative for neutralizing antibodies to the aavrh74var capsid are eligible for treatment with beqvez (fidanacogene elaparvovec). This diagnostic device is a single-site assay for professional use only and is to be performed only at labcorp-monogram biosciences by trained and qualified laboratory personnel. |
Approval Order | Approval Order |
Summary | Summary of Safety And Probable Benefit |
Labeling | Labeling
|